Total Payments
$52,865
2024 Payments
$158.67
Companies
8
Transactions
35
Medicare Patients
662
Medicare Billing
$64,744
Payment Breakdown by Category
Consulting$37,395 (70.7%)
Research$9,959 (18.8%)
Travel$4,668 (8.8%)
Food & Beverage$803.41 (1.5%)
Education$39.99 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,395 | 11 | 70.7% |
| Unspecified | $9,959 | 6 | 18.8% |
| Travel and Lodging | $4,668 | 9 | 8.8% |
| Food and Beverage | $803.41 | 8 | 1.5% |
| Education | $39.99 | 1 | 0.1% |
Payments by Type
General
$42,906
29 transactions
Research
$9,959
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $19,016 | 8 | $0 (2021) |
| AbbVie Inc. | $9,800 | 5 | $0 (2020) |
| Genentech USA, Inc. | $7,024 | 5 | $0 (2018) |
| F. Hoffmann-La Roche AG | $6,759 | 4 | $0 (2024) |
| Gilead Sciences Inc | $6,375 | 2 | $0 (2017) |
| Celgene Corporation | $3,796 | 9 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $55.00 | 1 | $0 (2022) |
| PFIZER INC. | $39.99 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $158.67 | 1 | F. Hoffmann-La Roche AG ($158.67) |
| 2023 | $6,640 | 4 | F. Hoffmann-La Roche AG ($6,600) |
| 2022 | $55.00 | 1 | AstraZeneca Pharmaceuticals LP ($55.00) |
| 2021 | $6,600 | 2 | Genentech, Inc. ($6,600) |
| 2020 | $6,370 | 3 | Genentech, Inc. ($4,620) |
| 2019 | $7,796 | 5 | Genentech, Inc. ($7,796) |
| 2018 | $15,074 | 8 | AbbVie, Inc. ($8,050) |
| 2017 | $10,171 | 11 | Gilead Sciences Inc ($6,375) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $158.67 | Research |
| Study: LEO DLBCL R R | ||||||
| 12/18/2023 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $39.99 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| 06/08/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| 01/20/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,980.00 | General |
| 12/09/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: Oncology | ||||||
| 10/01/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 03/26/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 06/06/2020 | Genentech, Inc. | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $4,620.00 | General |
| Category: None | ||||||
| 01/06/2020 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,260.00 | Research |
| Study: M15-550 • Category: ONCOLOGY | ||||||
| 01/06/2020 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $490.00 | Research |
| Study: M15-889 • Category: ONCOLOGY | ||||||
| 03/30/2019 | Genentech, Inc. | VENCLEXTA (Biological), Non-Covered Product | Food and Beverage | In-kind items and services | $300.25 | General |
| Category: BioOncology | ||||||
| 03/29/2019 | Genentech, Inc. | VENCLEXTA (Biological), Non-Covered Product | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: BioOncology | ||||||
| 03/29/2019 | Genentech, Inc. | VENCLEXTA (Biological), Non-Covered Product | Travel and Lodging | In-kind items and services | $1,096.97 | General |
| Category: BioOncology | ||||||
| 03/29/2019 | Genentech, Inc. | VENCLEXTA (Biological), Non-Covered Product | Travel and Lodging | In-kind items and services | $673.92 | General |
| Category: BioOncology | ||||||
| 03/29/2019 | Genentech, Inc. | VENCLEXTA (Biological), Non-Covered Product | Food and Beverage | In-kind items and services | $124.63 | General |
| Category: BioOncology | ||||||
| 12/21/2018 | AbbVie, Inc. | Venclexta (Drug) | — | Cash or cash equivalent | $3,850.00 | Research |
| Study: M14-728 • Category: Virology | ||||||
| 09/20/2018 | AbbVie, Inc. | Venclexta (Drug) | — | Cash or cash equivalent | $2,100.00 | Research |
| Study: M15-550 • Category: Virology | ||||||
| 09/20/2018 | AbbVie, Inc. | Venclexta (Drug) | — | Cash or cash equivalent | $2,100.00 | Research |
| Study: M15-889 • Category: Virology | ||||||
| 06/23/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, Non-Covered Product | Food and Beverage | In-kind items and services | $178.81 | General |
| Category: BioOncology/Immunology | ||||||
| 06/22/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, Non-Covered Product | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: BioOncology/Immunology | ||||||
| 06/22/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, Non-Covered Product | Travel and Lodging | In-kind items and services | $923.53 | General |
| Category: BioOncology/Immunology | ||||||
| 06/22/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, Non-Covered Product | Travel and Lodging | In-kind items and services | $245.37 | General |
| Category: BioOncology/Immunology | ||||||
| 06/22/2018 | Genentech USA, Inc. | Rituxan (Biological), GAZYVA, Non-Covered Product | Food and Beverage | In-kind items and services | $76.72 | General |
| Category: BioOncology/Immunology | ||||||
| 02/23/2017 | Celgene Corporation | Abraxane (Drug) | Travel and Lodging | Cash or cash equivalent | $25.91 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M14-728 | AbbVie, Inc. | $3,850 | 1 |
| M15-550 | AbbVie, Inc. | $2,100 | 1 |
| M15-889 | AbbVie, Inc. | $2,100 | 1 |
| M15-550 | AbbVie Inc. | $1,260 | 1 |
| M15-889 | AbbVie Inc. | $490.00 | 1 |
| LEO DLBCL R R | F. Hoffmann-La Roche AG | $158.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 165 | 221 | $71,827 | $11,695 |
| 2021 | 4 | 242 | 417 | $148,128 | $27,396 |
| 2020 | 4 | 255 | 440 | $164,837 | $25,654 |
Total Patients
662
Total Services
1,078
Medicare Billing
$64,744
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 106 | 122 | $30,870 | $4,639 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 42 | 70 | $26,254 | $4,246 | 16.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 29 | $14,703 | $2,810 | 19.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 62 | 144 | $53,468 | $9,597 | 17.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 131 | 185 | $46,355 | $8,537 | 18.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 31 | 69 | $34,633 | $6,626 | 19.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 19 | $13,672 | $2,636 | 19.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 50 | 139 | $68,363 | $11,314 | 16.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 72 | 138 | $50,406 | $7,434 | 14.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 120 | 150 | $36,950 | $5,229 | 14.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 13 | 13 | $9,118 | $1,677 | 18.4% |
About Dr. Brian Link, MD
Dr. Brian Link, MD is a Hematology & Oncology healthcare provider based in Iowa City, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1487635793.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Link, MD has received a total of $52,865 in payments from pharmaceutical and medical device companies, with $158.67 received in 2024. These payments were reported across 35 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($37,395).
As a Medicare-enrolled provider, Link has provided services to 662 Medicare beneficiaries, totaling 1,078 services with total Medicare billing of $64,744. Data is available for 3 years (2020–2022), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Iowa City, IA
- Active Since 11/14/2005
- Last Updated 07/13/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1487635793
Products in Payments
- Venclexta (Drug) $8,050
- VENCLEXTA (Biological) $7,796
- Rituxan (Biological) $7,024
- Non-Covered Product (Drug) $4,620
- Abraxane (Drug) $3,796
- VENCLEXTA (Drug) $1,750
- CALQUENCE (Drug) $55.00
- XTANDI (Drug) $39.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Iowa City
Umar Farooq, Md, MD
Hematology & Oncology — Payments: $20,985
Hematology & Oncology $20,985
George Weiner, Md, MD
Hematology & Oncology — Payments: $13,379
Hematology & Oncology $13,379
Usha Perepu, Mbbs, MBBS
Hematology & Oncology — Payments: $10,632
Hematology & Oncology $10,632
Dr. Laurel Lyckholm, M.d, M.D
Hematology & Oncology — Payments: $7,046
Hematology & Oncology $7,046
Guido Tricot, Md, MD
Hematology & Oncology — Payments: $5,537
Hematology & Oncology $5,537
Christopher Strouse, M.d, M.D
Hematology & Oncology — Payments: $4,364
Hematology & Oncology $4,364